Checkpoint Therapeutics, Inc.
CKPT
$4.04
$0.000.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -60.19% | -72.51% | -58.51% | -61.14% | -46.35% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -60.19% | -72.51% | -58.51% | -61.14% | -46.35% |
| Cost of Revenue | -17.02% | -44.16% | -49.37% | -28.92% | -12.56% |
| Gross Profit | 16.92% | 44.06% | 49.33% | 28.81% | 12.43% |
| SG&A Expenses | 131.01% | 6.76% | -1.17% | 1.09% | -0.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.59% | -36.11% | -42.42% | -24.53% | -10.72% |
| Operating Income | -7.72% | 36.01% | 42.37% | 24.42% | 10.60% |
| Income Before Tax | -8.47% | 13.53% | 27.57% | 6.99% | 17.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.47% | 13.53% | 27.57% | 6.99% | 17.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.47% | 13.53% | 27.57% | 6.99% | 17.21% |
| EBIT | -7.72% | 36.01% | 42.37% | 24.42% | 10.60% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 53.14% | 66.54% | 71.25% | 58.94% | 57.31% |
| Normalized Basic EPS | 53.14% | 66.55% | 71.25% | 58.94% | 57.31% |
| EPS Diluted | 53.14% | 66.54% | 71.25% | 58.94% | 57.31% |
| Normalized Diluted EPS | 53.14% | 66.55% | 71.25% | 58.94% | 57.31% |
| Average Basic Shares Outstanding | 111.01% | 143.14% | 151.51% | 143.07% | 106.54% |
| Average Diluted Shares Outstanding | 111.01% | 143.14% | 151.51% | 143.07% | 106.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |